Baptiste, P. J., Wong, A. Y. S., Schultze, A., Clase, C. M., Leyrat, C., Williamson, E., et al. (2024). Cardiorenal effects of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET). Am J Epidemiol.
Schultze, A., Martin, I., Messina, D., Bots, S., Belitser, S., Carreras-Martínez, J., et al. (2024). A comparison of four self-controlled study designs in an analysis of COVID-19 vaccines and myocarditis using five European databases. Vaccine, 42, 3039-3048.
Eroglu, T. E., Coronel, R., & Souverein, P. C. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. Eur Heart J Cardiovasc Pharmacother.
Shapiro, S. B., Yin, H., H. Y. Yu, O., & Azoulay, L. (2024). Sodium-glucose cotransporter-2 inhibitors and the risk of lung cancer among patients with type 2 diabetes. Br J Clin Pharmacol.
Pradhan, R., H. Y. Yu, O., Platt, R. W., & Azoulay, L. (2023). Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. Bmj Open Diabetes Res Care, 11.
Jödicke, A. M., Tan, E. H., Robinson, D. E., Delmestri, A., & Prieto-Alhambra, D. (2023). Risk of adverse events following the initiation of antihypertensives in older people with complex health needs: a self-controlled case series in the United Kingdom. Age Ageing, 52.
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab.
van Hulten, V., Driessen, J. H. M., Starup-Linde, J. K., Al-Mashhadi, Z. K., Viggers, R., Klungel, O. H., et al. (2023). The associations of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as add-on to metformin with fracture risk in patients with type 2 diabetes mellitus. Diabetes Obes Metab.
Ashworth, J., Bajpai, R., Muller, S., Bailey, J., Helliwell, T., Harrisson, S. A., et al. (2023). Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. The Lancet Regional Health - Europe, 27, 100579.
Jani, M., Yimer, B. B., Selby, D., Lunt, M., Nenadic, G., & Dixon, W. G. (2023). "Take up to eight tablets per day": Incorporating free-text medication instructions into a transparent and reproducible process for preparing drug exposure data for pharmacoepidemiology. Pharmacoepidemiol Drug Saf.